Figure 2From: The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial designTime to Amputation over 1 year BMAC vs. Control (Rutherford 5 patients only). There were no amputations in the Rutherford 4 group, removing these patients results in separation of the BMAC and control curves and demonstrates a trend towards a positive treatment effect on amputation. (p = 0.067)Back to article page